Lobbying Information
Subject Matters
- Aboriginal Affairs
- Economic Development
- Health
- Industry
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Policies or Program
- Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
- Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Finance Canada (FIN)
-
Health Canada (HC)
-
House of Commons
-
Indigenous Services Canada (ISC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
In-house Corporation Details
Description of activities
One of the world's leading research-driven pharmaceutical companies.
Responsible officer name and position during the period of this registration
Andrea Sambati,
President, CEO
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
5180 South Service Road
Burlington, ON L7L 5H4
Canada
Telephone number:
289-208-7527
Parent Company Information
Boehringer Ingelheim Canada Ltd. is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
Boehringer Ingelheim Canada Ltd. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Andrea Sambati,
President, CEO |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Mehmood Alibhai,
Director of Patient Access & Healthcare Policy |
No public offices held
- Gerald McCarron,
Manager, External & Healthcare Affairs |
No public offices held
- Andrew Ransom,
Manager, Patient Access |
No public offices held
